Jake Leach
speaker
301 appearances
1 recordings
1 series
first heard Feb 2026
last heard 19 Feb
Jake Leach’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 1 in all, peaking in Feb 2026 with 1.
Appearances
So that product has really expanded the use of CGM.
And we see a lot of people who have type 2 diabetes but don't yet have coverage for CGM.
If they had coverage, they'd use G7, but they don't.
So many of our patients on Stello are type 2s that are basically getting the technology and benefiting from it while we wait for their reimbursement to come.
In the long run, there is an opportunity to have a CGM that's reimbursed, just like Stello.
But what we see happening is as reimbursement continues to expand, G7 is in the United States here.
That's the platform that is covered.
And we'll continue to innovate on G7, actually bring some of the Stello features.
Mm-hmm.
That we've been able to innovate there over to the G7 platform for the users that can benefit.
As we see a broader population of users and different segments start to use G7, we'll keep innovating.
G7, you know, the original CGMs were really focused for type 1 diabetes.
And as we've expanded our portfolio over time, we started designing for type 1, type 2 on insulin.
And now we're starting to see a lot more coverage come for anybody with diabetes.
So not only those that treat their diabetes with insulin, but any other medication.
And so as we see that expand, we'll keep innovating on the product to meet those needs.
And, you know, someday there's a possibility where we could even see prediabetes covered.
If you think about the 100 million people in the United States have prediabetes.
Mm-hmm.
on their way to diabetes.
Showing 121–140 of 301 · page 7 of 16
← Previous
Next →